BATLIGAP Trademark

Trademark Overview


On Thursday, September 16, 2021, a trademark application was filed for BATLIGAP with the United States Patent and Trademark Office. The USPTO has given the BATLIGAP trademark a serial number of 97031263. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Thursday, August 15, 2024. This trademark is owned by Eli Lilly and Company. The BATLIGAP trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases
batligap

General Information


Serial Number97031263
Word MarkBATLIGAP
Filing DateThursday, September 16, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateThursday, August 15, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 19, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, October 21, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Thursday, October 21, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, September 20, 2021NEW APPLICATION ENTERED
Wednesday, June 15, 2022ASSIGNED TO EXAMINER
Wednesday, June 15, 2022EXAMINER'S AMENDMENT ENTERED
Wednesday, June 15, 2022EXAMINERS AMENDMENT -WRITTEN
Wednesday, June 15, 2022EXAMINERS AMENDMENT E-MAILED
Wednesday, June 15, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, June 15, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 29, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, July 7, 2022ASSIGNED TO EXAMINER
Tuesday, July 19, 2022PUBLISHED FOR OPPOSITION
Tuesday, July 19, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 13, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, February 15, 2023SOU EXTENSION 1 FILED
Wednesday, February 15, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, August 15, 2023SOU TEAS EXTENSION RECEIVED
Thursday, August 17, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 3, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Saturday, March 4, 2023SOU EXTENSION 1 GRANTED
Tuesday, March 7, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 15, 2023SOU EXTENSION 2 FILED
Tuesday, August 15, 2023SOU EXTENSION 2 GRANTED
Monday, February 19, 2024SOU TEAS EXTENSION RECEIVED
Monday, February 19, 2024SOU EXTENSION 3 FILED
Monday, February 19, 2024SOU EXTENSION 3 GRANTED
Thursday, August 15, 2024SOU TEAS EXTENSION RECEIVED
Thursday, August 15, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 15, 2024SOU EXTENSION 4 GRANTED
Thursday, August 15, 2024SOU EXTENSION 4 FILED
Tuesday, February 20, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED